ArticleEuropean journal of nuclear medicine and molecular imaging2025
Quantitative
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Authors' Reply: Clarifying the Comparative Interpretation and Clinical Implications of Radiomics-Based AI for Pathological Response Prediction.Journal of medical Internet research · 2026Article
- Same-Patient, Same-Time Point Evidence for Radiomics Benchmarking.Journal of medical Internet research · 2026Article
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.Nature reviews. Clinical oncology · 2026Review
- PET/CT predict pathological response to neoadjuvant nivolumab in resectable non-small cell lung cancer.European journal of nuclear medicine and molecular imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThis study aimed to evaluate the predictive value of
methodA retrospective review was conducted on patients with resectable NSCLC who received neoadjuvant immunochemotherapy from January 2020 to December 2023. Patients with both pre-treatment (
results36 patients were included for model development, with 19 (52.8%) achieving pCR. ΔTLR% (percentage change between two scans in tumor-to-liver ratio) and SUL
conclusionsThis study suggests that
Indexed as
Identifiers
40418330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.